{"groups":[{"description":"Patients receive oral deferasirox once daily for up to 6 months or until blood counts recover in the absence of disease progression or unacceptable toxicity.\n\ndeferasirox : Given orally\n\nlaboratory biomarker analysis : Correlative studies\n\nenzyme-linked immunosorbent assay : Correlative studies","id":"FG000","title":"Arm I"},{"description":"blood tested on healthy patients","id":"FG001","title":"Control Arm"},{"description":"treated off study with or without oral deferasirox (patient choice) but lab draws to gather lab analysis","id":"FG002","title":"Correlative"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"5"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"5"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}